TLDR The study found that prescribing patterns for Cyproterone Acetate/Ethinylestradiol in Italy did not significantly change after EMA recommendations.
The study analyzed the prescription patterns of Cyproterone Acetate/Ethinylestradiol (CPA/EE) in Italy, using data from 1,189 new users (495 in 2011, 446 in 2012, and 261 in 2014) to determine if prescribing practices changed following the European Medicines Agency's (EMA) 2013 recommendation on CPA/EE's risk profile. The findings showed that the concomitant use of CPA/EE with other hormonal contraceptives was low (1% in 2011-2012 and 2% in 2014) and that the proportion of patients with acne or other hyperandrogenic conditions remained consistent before and after the EMA recommendation. Despite a decrease in CPA/EE prescriptions, there was no significant change in the prescription appropriateness for hyperandrogenic conditions or in the concomitant use of other hormonal contraceptives. The study highlighted the importance of following prescribing guidelines to ensure the safe use of CPA/EE.View this study on link.springer.com →
The medication cyproterone acetate/ethinylestradiol is usually prescribed correctly for acne after other treatments don't work.
The study found that prescribing patterns for Cyproterone Acetate/Ethinylestradiol in Italy did not significantly change after EMA recommendations.